Skip to main content

Compare Stocks

Date Range: 

 ImmunoGenPrelude TherapeuticsTravere TherapeuticsApplied Molecular TransportDiaMedica Therapeutics
Price Information
Current Price$6.75$42.04$18.27$44.70$6.50
52 Week RangeBuyHoldBuyBuyN/A
Overall Score1.
Analysis Score3.
Community Score2.
Dividend Score0.
Ownership Score1.
Earnings & Valuation Score0.
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyN/A
Consensus Price Target$10.10$55.80$42.67$68.75N/A
% Upside from Price Target49.63% upside32.73% upside133.53% upside53.80% upsideN/A
Trade Information
Market Cap$1.35 billion$1.49 billion$1.10 billion$1.58 billion$1.02 billion
Average Volume2,214,574223,111605,309227,360131,151
Sales & Book Value
Annual Revenue$82.27 millionN/A$175.34 millionN/AN/A
Price / Sales16.40N/A6.30N/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($0.51) per shareN/A$5.15 per shareN/AN/A
Price / Book-13.24N/A3.55N/AN/A
Net Income$-104,130,000.00N/A$-146,430,000.00$-28,040,000.00$-2,220,000.00
Trailing P/E RatioN/A0.00N/A0.000.00
Forward P/E RatioN/AN/AN/AN/AN/A
Net Margins-77.65%N/A-40.24%N/AN/A
Return on Equity (ROE)N/AN/A-29.27%N/AN/A
Return on Assets (ROA)-26.98%N/A-12.25%N/AN/A
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt-to-Equity RatioN/AN/A0.71%N/AN/A
Current Ratio2.20%20.96%6.60%19.39%N/A
Quick Ratio2.20%20.96%6.50%19.39%N/A
Ownership Information
Institutional Ownership Percentage72.95%76.21%N/A51.99%N/A
Insider Ownership Percentage3.77%N/A4.63%N/AN/A
Shares Outstanding199.94 million35.50 million60.46 million35.25 million157.14 million
Next Earnings Date7/30/2021 (Estimated)8/10/2021 (Estimated)7/29/2021 (Estimated)8/10/2021 (Estimated)N/A
OptionableOptionableNot OptionableOptionableNot OptionableNot Optionable
5/10/2021ImmunoGenWilliam BlairReiterated Rating
2/16/2021ImmunoGenHC WainwrightBoost Price Target
12/7/2020ImmunoGenPiper SandlerBoost Price Target
11/6/2020ImmunoGenSVB LeerinkBoost Price Target
10/20/2020ImmunoGenCanaccord GenuityReiterated Rating
9/29/2020ImmunoGenJPMorgan Chase & Co.Initiated Coverage
12/10/2019ImmunoGenCowenReiterated Rating
3/23/2021Prelude TherapeuticsMorgan StanleyBoost Price Target
3/9/2021Prelude TherapeuticsBarclaysInitiated Coverage
11/20/2020Prelude TherapeuticsBank of AmericaDowngrade
10/20/2020Prelude TherapeuticsThe Goldman Sachs GroupInitiated Coverage
5/7/2021Travere TherapeuticsBMO Capital MarketsLower Price Target
4/12/2021Travere TherapeuticsWedbushLower Price Target
11/23/2020Travere TherapeuticsEvercore ISIInitiated Coverage
3/23/2021Applied Molecular TransportJefferies Financial GroupBoost Price Target
3/23/2021Applied Molecular TransportJMP SecuritiesInitiated Coverage
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.